Comparative Pharmacology
Head-to-head clinical analysis: ACTHAR GEL AUTOINJECTOR versus CORTICOTROPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTHAR GEL AUTOINJECTOR versus CORTICOTROPIN.
ACTHAR GEL (AUTOINJECTOR) vs CORTICOTROPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTHAR Gel (repository corticotropin injection) acts primarily by stimulating the adrenal cortex to secrete corticosteroids (cortisol, corticosterone, and aldosterone), which exert anti-inflammatory, immunosuppressive, and antiproliferative effects. The exact mechanism in specific indications (e.g., infantile spasms) is not fully understood but may involve modulation of the hypothalamic-pituitary-adrenal axis and direct effects on the central nervous system.
Corticotropin (ACTH) stimulates the adrenal cortex to release cortisol, corticosterone, aldosterone, and androgens via activation of melanocortin 2 receptor (MC2R) in the zona fasciculata and reticularis.
Initial: 40-80 units intramuscularly or subcutaneously every 24-48 hours; maintenance: 20-40 units intramuscularly or subcutaneously every 48 hours. Titrate based on response.
40-80 units IM or SC every 24-72 hours; dose adjusted based on response.
None Documented
None Documented
The terminal half-life of exogenously administered ACTH is approximately 15 minutes; however, the duration of adrenal cortisol stimulation persists for 6-12 hours after IM administration due to prolonged absorption from the gel formulation.
15-30 minutes (intravenous); clinically, duration of action (via adrenal stimulation) exceeds half-life due to sustained cAMP-mediated effects.
ACTH (corticotropin) is metabolized by tissue peptidases; renal excretion accounts for <5% of unchanged drug. Biliary/fecal elimination is negligible.
Primarily metabolized in tissues via proteolysis; negligible renal excretion of intact hormone (<5%); urinary metabolites include small peptide fragments.
Category C
Category C
Corticotropin
Corticotropin